Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Appointed director CC transcript Acq. announced
|
Talon Therapeutics, Inc. (TLON)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/28/2017 |
CT ORDER
| Form CT ORDER - Confidential treatment order |
12/29/2016 |
CT ORDER
| Form CT ORDER - Confidential treatment order |
07/29/2013 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)] |
07/25/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
07/25/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
07/25/2013 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
07/25/2013 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
07/25/2013 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
07/25/2013 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
07/25/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
07/25/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
07/25/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
07/25/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
07/25/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
07/25/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
07/25/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
07/25/2013 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
07/19/2013 |
8-K
| Quarterly results |
07/18/2013 |
4
| WEATHERMAN ELIZABETH H (Director) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Converted 65,016,890 shares
@ $0.736, valued at
$47.9M
Converted 37,775,503 shares
@ $0.3, valued at
$11.3M
Converted 49,537,551 shares
@ $0.35, valued at
$17.3M
Sold 152,329,944 shares
@ $0.06, valued at
$9.1M
Converted 360,000 options to buy
@ $100, valued at
$36M
Converted 11,307 preferred shares
@ $100, valued at
$1.1M
Converted 99,000 options to buy
@ $100, valued at
$9.9M
Converted 27,000 options to buy
@ $100, valued at
$2.7M
Converted 54,000 options to buy
@ $100, valued at
$5.4M
Disposed of 420,000 options to buy
@ $0 |
|
07/18/2013 |
4
| WARBURG PINCUS & CO. (10% Owner) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Converted 65,016,890 shares
@ $0.736, valued at
$47.9M
Converted 37,775,503 shares
@ $0.3, valued at
$11.3M
Converted 49,537,551 shares
@ $0.35, valued at
$17.3M
Sold 152,329,944 shares
@ $0.056, valued at
$8.5M
Converted 360,000 options to buy
@ $100, valued at
$36M
Converted 11,307 preferred shares
@ $100, valued at
$1.1M
Converted 99,000 options to buy
@ $100, valued at
$9.9M
Converted 27,000 options to buy
@ $100, valued at
$2.7M
Converted 54,000 options to buy
@ $100, valued at
$5.4M
Disposed of 420,000 options to buy
@ $0 |
|
07/18/2013 |
SC 13D/A
| Warburg Pincus Private Equity X, L.P. reports a 0% stake in Talon Therapeutics, Inc. |
07/18/2013 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
07/18/2013 |
4
| Flynn James E (10% Owner) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Converted 424,798 shares
@ $0.736, valued at
$312.7k
Converted 837,215 shares
@ $0.3, valued at
$251.2k
Converted 322,911 shares
@ $0.35, valued at
$113k
Sold 1,619,176 shares
@ $0.0561, valued at
$90.8k
Converted 778,856 shares
@ $0.736, valued at
$573.2k
Converted 1,535,573 shares
@ $0.3, valued at
$460.7k
Converted 592,613 shares
@ $0.35, valued at
$207.4k
Sold 2,974,566 shares
@ $0.0561, valued at
$166.9k
Converted 2,305,753 shares
@ $0.736, valued at
$1.7M
Converted 4,545,880 shares
@ $0.3, valued at
$1.4M
Converted 1,757,664 shares
@ $0.35, valued at
$615.2k
|
|
07/18/2013 |
4
| Spiegel Robert J. (Director) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Disposed/sold 10,000 options to buy
@ $0.68, valued at
$6.8k
Disposed/sold 35,000 options to buy
@ $0.77, valued at
$27k
Disposed/sold 35,000 options to buy
@ $0.905, valued at
$31.7k
Disposed/sold 35,000 options to buy
@ $0.64, valued at
$22.4k
|
|
07/18/2013 |
4
| Rosenberg Leon E (Director) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Disposed/sold 250 shares
@ $0 Disposed/sold 7,050 options to buy
@ $6.736, valued at
$47.5k
Disposed/sold 5,000 options to buy
@ $5.32, valued at
$26.6k
Disposed/sold 5,000 options to buy
@ $6.6, valued at
$33k
Disposed/sold 10,000 options to buy
@ $19, valued at
$190k
Disposed/sold 10,000 options to buy
@ $27.28, valued at
$272.8k
Disposed/sold 8,750 options to buy
@ $8.16, valued at
$71.4k
Disposed/sold 18,750 options to buy
@ $4.48, valued at
$84k
Disposed/sold 18,750 options to buy
@ $0.56, valued at
$10.5k
Disposed/sold 18,750 options to buy
@ $0.76, valued at
$14.3k
Disposed/sold 65,000 options to buy
@ $0.77, valued at
$50.1k
|
|
07/18/2013 |
4
| PIEN HOWARD H (Director) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Disposed/sold 50,000 options to buy
@ $0.82, valued at
$41k
Disposed/sold 35,000 options to buy
@ $0.64, valued at
$22.4k
|
|
07/18/2013 |
4
| MAIER PAUL V (Director) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Disposed/sold 1,750 shares
@ $0 Disposed/sold 10,000 options to buy
@ $3.6, valued at
$36k
Disposed/sold 2,500 options to buy
@ $2.92, valued at
$7.3k
Disposed/sold 12,500 options to buy
@ $0.56, valued at
$7k
Disposed/sold 12,500 options to buy
@ $0.76, valued at
$9.5k
Disposed/sold 47,000 options to buy
@ $0.77, valued at
$36.2k
Disposed/sold 47,000 options to buy
@ $0.905, valued at
$42.5k
Disposed/sold 47,000 options to buy
@ $0.64, valued at
$30.1k
|
|
07/18/2013 |
4
| Gharib Samir M. (Controller, Direct. of Finance) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Disposed/sold 75,000 options to buy
@ $0.485, valued at
$36.4k
Disposed/sold 50,000 options to buy
@ $0.64, valued at
$32k
|
|
07/18/2013 |
4
| Furst Howard P. (Director) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Disposed/sold 10,000 options to buy
@ $0.76, valued at
$7.6k
Disposed/sold 35,000 options to buy
@ $0.77, valued at
$27k
Disposed/sold 35,000 options to buy
@ $0.905, valued at
$31.7k
Disposed/sold 35,000 options to buy
@ $0.64, valued at
$22.4k
|
|
07/18/2013 |
4
| DeZao Thomas (VP, Comm. Oper. & Planning) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Disposed/sold 200,000 options to buy
@ $0.745, valued at
$149k
Disposed/sold 100,000 options to buy
@ $0.64, valued at
$64k
|
|
07/18/2013 |
4
| DEITCHER STEVEN R (President & CEO) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Disposed/sold 184,192 shares
@ $0 Disposed/sold 100,000 options to buy
@ $6.6, valued at
$660k
Disposed/sold 25,000 options to buy
@ $6.96, valued at
$174k
Disposed/sold 162,500 options to buy
@ $4.48, valued at
$728k
Disposed/sold 75,000 options to buy
@ $0.56, valued at
$42k
Disposed/sold 312,500 options to buy
@ $0.76, valued at
$237.5k
Disposed/sold 87,500 options to buy
@ $0.92, valued at
$80.5k
Disposed/sold 1,635,000 options to buy
@ $0.495, valued at
$809.3k
Disposed/sold 1,000,000 options to buy
@ $0.905, valued at
$905k
Disposed/sold 1,000,000 options to buy
@ $0.64, valued at
$640k
|
|
07/18/2013 |
4
| CARLSON CRAIG W (CFO) has filed a Form 4 on Talon Therapeutics, Inc.
Txns:
| Disposed/sold 87,500 options to buy
@ $0.76, valued at
$66.5k
Disposed/sold 62,500 options to buy
@ $0.92, valued at
$57.5k
Disposed/sold 705,000 options to buy
@ $0.495, valued at
$349k
Disposed/sold 400,000 options to buy
@ $0.905, valued at
$362k
Disposed/sold 400,000 options to buy
@ $0.64, valued at
$256k
|
|
07/17/2013 |
8-K
| Other Events, Financial Statements and Exhibits |
05/15/2013 |
10-Q
| Quarterly Report for the period ended March 31, 2013 |
|
|
|